Alzheimer's actually gets a lot of funding, but mostly for therapeutics, not diagnostics: it gets a lot of funding from NIH, and neurodegenerative disease trea

Alzheimer's actually gets a lot of funding, but mostly for therapeutics, not diagnostics: it gets a lot of funding from NIH, and neurodegenerative disease treatments get the third or fourth most VC and big pharma funding (after cancer, rare disease and maybe infectious disease) However none of the drugs really work, and ppl think one reason is bc patients are diagnosed too late Diagnostics get very little funding in general, not just in Alzheimer's. Calling yourself a "diagnostics" company is a good way to get ignored by VCs. You have to do a lot of expensive studies to prove that they work, the bar is quite high to getting insurers to pay for them, and pricing power is low. Most insurers will only pay for a novel diagnostic if it saves them money. So you have high development cost and low profit potential